The AMR Accelerator programme comprises 7 projects and has 57 participants operating in 14 countries.

Organisations such as universities, research institutes, EFPIA companies, and small and mid-sized companies across Europe, and beyond, collaborate in public-private partnerships, unified by a common goal of developing new tools and therapeutics to fight resistant pathogens, with a particular focus on targeting tuberculosis (TB) and Gram-negative infections.


Antimicrobial resistance knows no boundaries – neither should we!


Click on the map below to find out more about AMR Accelerator partners:
Disclaimer: This map is for graphical purposes only.  The presentation of data on this map does not represent any legal or political reference.  While every effort has been made to ensure that these data are reliable and accurate within the limits of the current state of the art, COMBINE does not assume liability for any omissions or inaccuracies in the data, nor as a result of the failure of the data to function on a particular system. 

Organisation

AMR Accelerator project(s)

Asclepia Outsourcing Solutions COMBINE
BEAM Alliance COMBINE
Bill & Melinda Gates Foundation ERA4TB
BIOASTER GNA NOW & ERA4TB
BIOCOM AG COMBINE
BioVersys Tric-TB
Centre Hospitalier Régional Universitaire de Tours AB-Direct
Centre Hospitalier Universitaire de Poitiers AB-Direct
Clinical Studies Sweden Forum South ERA4TB
Consiglio Nazionale delle Richerche ERA4TB
Critical Path Institute  ERA4TB
École polytechnique fédérale de Lausanne ERA4TB
Erasmus MC – University Medical Center Rotterdam GNA NOW
Evotec ERA4TB, COMBINE & GNA NOW
FFUND BV Respiri-TB & Respiri-NTM
Foundation Innovative Medicines for Tuberculosis ERA4TB
Fraunhofer IME COMBINE & GNA NOW
grit42 COMBINE & ERA4TB
GSK ERA4TB, COMBINE, AB-Direct & Tric-TB
Helmholtz Centre for Infection Research GNA NOW
Helmholtz Institute for Pharmaceutical Research Saarland GNA NOW
ImaBiotech ERA4TB
Infectious Diseases Models for Innovative Therapies ERA4TB
Inserm GNA NOW & AB-Direct
Institute Pasteur ERA4TB
Institute Pasteur de Lille Foundation ERA4TB
Instituto de Investigación Hospital Universitario La Paz ERA4TB
Janssen Pharmaceutica COMBINE, Respiri-TB & Respiri-NTM & ERA4TB
Latvian Institute of Organic Synthesis ERA4TB
Leiden University Medical Center Respiri-TB and Respiri-NTM
Lygature GNA NOW
Medical University of Vienna GNA NOW, AB-Direct, Respiri-TB & Respiri-NTM
Mitologics Respiri-TB & Respiri-NTM
North Bristol NHS Trust GNA NOW
Nosopharm GNA NOW
Paul-Ehrlicht-Institut COMBINE
Public Health England ERA4TB
QPS Netherlands ERA4TB
Research Center Borstel ERA4TB
Sciensano ERA4TB
Sorbonne University Respiri-TB & Respiri-NTM
Statens Serum Institut COMBINE
Synapse Management Partners ERA4TB
TB Alliance ERA4TB
The National Institute for Health and Care Excellence ERA4TB
University Carlos III Madrid ERA4TB
University Leiden Respiri-TB & Respiri-NTM
University of Antwerp Respiri-TB & Respiri-NTM
University of Copenhagen Respiri-TB & Respiri-NTM
University of Dundee ERA4TB
University of Köln ERA4TB
University of Liverpool GNA NOW
University of Padova ERA4TB
University of Pavia ERA4TB
University of Poititers GNA NOW & AB-Direct
University of Zaragoza ERA4TB
Uppsala University COMBINE & ERA4TB